I

The letter from Pharmabody arrived on a Thursday. Jack Morrisey almost threw it away—he threw away a lot of mail, most of it bills, some of it collection notices—but the return address caught his eye: Pharmabody Clinical Trials, Youngstown, Ohio.

He sat at the kitchen table with his coffee and read it. The letter offered him a spot in a "groundbreaking gene therapy program" for patients with advanced pulmonary disease. The language was carefully chosen: "revolutionary," "hope," "the future of medicine." It was written by someone who understood how to make a man in his forties with a death sentence sound like a lottery winner.

Jack had worked the welding line at Ford's Mahoning Valley plant for twenty-five years. He knew what happened to men who spent their lives breathing metal dust. His lungs were slowly turning to stone. The doctor had used the word "fibrosis" and then said, in a voice that was careful but not unkind, that there was no treatment for it except a transplant, and Jack did not qualify for one because of his age and his other health problems.

The letter said he qualified for the experiment. The appointment was in two weeks.

Amy, his nineteen-year-old daughter, was at community college during the day and worked the shift register at a grocery store at night. She did not know about the letter. She did not know about the letter about the letter that had come a week before, from the VA, informing him that his disability claim had been denied.

Jack put the letter in his desk drawer and went to work.

II

The first infusion went smoothly. The second, too. Jack was told to expect mild side effects—fatigue, nausea, a metallic taste in his mouth. He experienced none of these. He felt, for the first time in years, better than fine. He climbed the stairs to his second-floor bedroom without stopping. He could speak three blocks without the rattling breath that had become his constant companion.

The Pharmabody clinic was a modern building on the outskirts of Youngstown, all glass and steel and the kind of landscaping that cost more than Jack made in a month. The nurses were young and cheerful and spoke to him the way you speak to a child who has done something impressive.

"Mr. Morrisey, your pulmonary function tests are remarkable," said the doctor, a woman with sharp features and a voice that suggested she had never been surprised by anything but was nevertheless pleased. "The cellular replacement is proceeding exactly as planned."

"Replacement," Jack repeated. "Right. You're putting new cells in my lungs."

"Replacing the damaged tissue," she corrected gently. "Your new cells are integrating beautifully."

Jack looked at her and nodded. He did not ask what the new cells looked like, or where they had come from, or whether they felt different from the old ones. He was feeling better, and that was enough.

The third month brought the first symptom. A rash on Jack's forearms—patches of opaque, slightly raised skin that were neither itchy nor painful. The doctor at the clinic said it was a normal part of the adjustment process. "Your body is learning to work with new cells," she said. "It will fade."

It did not fade. It spread. The patches grew larger and harder, turning from skin-colored to a faintly grayish white, like the surface of a river stone.

Jack began to notice other things. His blood work showed an elevated white cell count, but the doctor said that was expected. His energy levels fluctuated—some days he felt great, others he felt like the old Jack, the one who could not climb stairs without stopping. The doctor said that was normal too. "Cellular integration is not linear," she said. "It ebbs and flows."

In the sixth month, a journalist from the Columbus Dispatch called Pharmabody for a story about clinical trials in Ohio. During the interview, the journalist asked a routine question: "How many patients have reported adverse effects?"

The PR representative's answer was careful but revealing: "Adverse effects are rare in our Phase III trials. The vast majority of patients report significant improvement in quality of life."

Rare. Jack had not seen any of the other patients. He did not know if the rash was rare or common. He went to a dermatologist in Cleveland who had never heard of Pharmabody and who, when she examined the patches on Jack's arms, frowned and said, "I've never seen anything like this. I'm going to do a biopsy."

The biopsy showed cells that were not entirely human.

III

Jack did not understand what the biopsy meant. The Cleveland doctor did not either. She called a specialist, who called another specialist, and by the end of the week, the case had been forwarded to the Centers for Disease Control.

Jack sat in his kitchen, staring at a stack of mail he had not opened, and thought about the word rare. The doctor had said rare. The PR representative had said rare. But rare did not mean never.

He found a former coworker, Rick Palmer, who had also participated in the Pharmabody trial. Rick was worse off. His hands were deformed—the fingers fused at the joints, the nails grown thick and clawlike. He spoke through a voice that was raspy and thin, as if his vocal cords were also changing.

"They told me not to talk about it," Rick said. "They said if I caused a panic, they'd pull me from the program and I'd be on my own."

"What's happening to us?" Jack asked.

Rick looked at his hands, at the thick claws that had replaced his fingers, and shrugged. The shrug was painful. "I think the new cells aren't replacing the old ones. I think they're taking over."

Jack went to the Pharmabody clinic and demanded to see his records. The receptionist said he would need an appointment. He said he did not have time for appointments. He said he wanted to see the doctor who had overseen his treatment.

He was escorted to a small office by a man in a suit who introduced himself as the director of patient relations. The man's name was Brian, and he was polite and firm and said the words Jack had been waiting to hear without sounding like he was saying them.

"Mr. Morrisey, the therapy we provide is experimental. As such, there are risks that cannot be fully predicted or controlled. When you signed the consent forms, you acknowledged these risks."

"I didn't know 'risks' meant my body stops being mine," Jack said.

Brian smiled the smile of a man who had practiced this exact expression in a mirror. "Your body is not stopping being yours, Mr. Morrisey. The cells are integrating. This is the intended outcome."

Jack looked at him for a long time. Then he got up, walked out of the office, and went home.

IV

The phone rang the next morning. It was Amy. "Dad, I found something online. It's about Pharmabody."

Jack listened as she read to him from a document that had been leaked—a set of internal emails between Pharmabody executives discussing "patient outcomes" and "liability exposure" and "the consent forms hold up legally even in cases of significant cellular integration."

He said nothing. He stood at the kitchen window and watched the street outside, where a man was mowing his lawn with the mechanical indifference of someone who had nothing else to do with his Tuesday morning.

The phone rang again. This time, it was a letter—not a letter, a packet. A follow-up invitation from Pharmabody: "We are pleased to invite you to participate in Phase II of our cellular enhancement program. Phase I has shown remarkable results in pulmonary improvement. Phase II will focus on full cellular integration and systemic optimization."

Jack put the invitation on the table beside his coffee cup and sat down. His arms ached where the patches of gray skin had spread. He could feel, deep in his chest, the new cells working—replacing, integrating, taking over, the way water replaces stone in a pipe, slowly, silently, inevitably.

He did not know what was going to happen to him. He did not know whether the new cells would stop at his lungs or continue spreading, whether his body would become something that was still human or something else entirely.

He knew one thing: he was going to fight. Not with lawyers or protesters or media stories. He was going to fight the way a man fights when he has nothing—by enduring, by surviving, by sitting at his kitchen table and refusing to be erased.

Amy came home from work that evening and found him at the table, the Pharmabody invitation beside his coffee cup, a pen in his hand.

"What are you doing, Dad?"

"Writing," he said. "I'm writing down everything. Every symptom. Every clinic visit. Every word they said to me."

"For what?"

"So when they tell me my body isn't mine anymore, I'll have proof that it was mine first."

OTMES V2 Code: - TI: 65.0 (T2 幻灭级) - M: [7.0, 0.5, 3.0, 2.0, 4.0, 4.0, 4.0, 5.0, 1.0, 3.0] - N: [0.50, 0.50] - K: [0.60, 0.40] - Theta: 160 deg (被动承受型) - V: 0.65, I: 0.80, C: 0.20, S: 0.40, R: 0.15 - Core: (M1_悲剧, N2_被动, K1_感性) - Style: E - Dirty Realism